Burning Rock Biotech Limited reported financial results for the second quarter ended June 30, 2026. Total revenues decreased 9.3% to RMB134.7 million (US$19.9 million) from RMB148.5 million in the prior year period. In-hospital business revenue rose 7.4% to RMB67.1 million, while central laboratory and pharma research revenues declined by 10.0% and 31.8%, respectively. Gross profit fell 9.5% to RMB97.8 million with a gross margin of 72.6%. Operating expenses decreased 3.2% to RMB115.8 million, driven by lower research and development costs. The company reported a net loss of RMB18.4 million (US$2.7 million) compared to RMB9.7 million in the same period last year. Cash and equivalents stood at RMB416.8 million as of June 30, 2026. Several diagnostic kits entered priority or special review channels with the NMPA. Burning Rock Biotech Limited operates in the precision oncology industry, applying next-generation sequencing technology for cancer therapy selection and early detection.